Dana Chase, MD, FACOG, gynecologic oncologist, discusses the importance of utilizing genetic testing for BRCA mutations in ovarian cancer.
Dana Chase, MD, FACOG
Advertisement
Articles by Dana Chase, MD, FACOG
Dana Chase, MD, FACOG, discusses the importance of utilizing genetic testing to guide treatment decisions for patients with ovarian cancer.
Dana Chase, MD, FACOG, discusses the safety profile of niraparib as frontline maintenance therapy in ovarian cancer.
Advertisement
Latest Updated Articles
Dr. Chase on Toxicities With Niraparib in Ovarian CancerPublished: April 11th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
5